

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

NCI-H2110

RRID:CVCL_1530

Type: Cell Line

Proper Citation

RRID:CVCL_1530

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1530

Proper Citation: RRID:CVCL_1530

Description: Cell line NCI-H2110 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Lung non-small cell carcinoma

Defining Citation: [PMID:8806092](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2110

Synonyms: H2110, H-2110, NCIH2110

Cross References: BTO:BTO_0006021, CLO:CLO_0008054, EFO:EFO_0006673, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5924, BioGRID_ORCS_Cell_line:532, BioSample:SAMN03473198, BioSample:SAMN10987977, cancercellines:CVCL_1530, Cell_Model_Passport:SIDM00703, CLS:305838, Cosmic:1146901, Cosmic-CLP:1298351, DepMap:ACH-000929, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298351, GEO:GSM434270, GEO:GSM887405, GEO:GSM888484,

GEO:GSM1670216, IGRhCellID:H2110GEO, LiGeA:CCLE_265, LINCS_LDP:LCL-1616, PharmacDB:NCIH2110_1069_2019, PRIDE:PXD030304, Progenetix:CVCL_1530, Wikidata:Q54907926

ID: CVCL_1530

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260829T234741+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2110.

No alerts have been found for NCI-H2110.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Mozzarelli AM, et al. (2025) RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma. *Cancer research*, 85(17), 3196.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. *Nature*.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC ? in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. *Cell reports*, 43(8), 114622.

Riley AK, et al. (2024) The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. *iScience*, 27(8), 110499.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.